Tilray® Receives Complete GMP Certification at EU Campus
May 27 2020 - 8:00AM
Business Wire
Licensing expands company’s international export capacity to
serve authorized medical cannabis markets
Provides authorization to complete medical cannabis
extraction on-site and the production of bulk extracts to
manufacture medical cannabis oil as a finished product
Certification signals another milestone for EU campus as
Tilray’s international medical cannabis hub
Tilray, Inc. (“Tilray” or the “Company”) (NASDAQ: TLRY), a
global pioneer in cannabis research, cultivation, production and
distribution, today announced its wholly-owned subsidiary Tilray
Portugal, Unipessoal Lda. (“Tilray Portugal”) has received a Good
Manufacturing Practice (GMP) certification in accordance with
European Union standards, for its manufacturing facility in
Cantanhede, Portugal. The GMP certification was issued by Infarmed,
the Portuguese National Authority of Medicines and Health Products
which provides end-to-end GMP certification for Tilray’s current
operations in Portugal.
This is the third GMP certification for Tilray Portugal, which
allows the facility to manufacture medical cannabis extracts
in-house and export GMP-produced finished medical cannabis
products, both dried flower and oil, from Portugal throughout
European Union and other international markets with legal medical
cannabis regulations. Further, the additional certification
authorizes Tilray to manufacture bulk extracts on-site to sell as
cannabis API (active pharmaceutical ingredients) and provides
additional quality control lab capacity to further advance the
Company’s ability for product innovation and research.
“This is an important milestone for our strategic growth in the
international medical cannabis market,” says Sascha Mielcarek,
Tilray’s Managing Director in Europe. “Our third GMP certification
will enable us to manufacture more products at our facility and
export a greater range of medical products to international
patients, partners and markets. As demand increases around the
world and more legal medical cannabis markets emerge, Tilray’s EU
campus is ready to serve more partners and patients across the EU
and other international medical markets.”
Tilray has announced the previous license issuances, GMP
certifications, and exports:
- Initial licensing and GMP Certification: In May 2019,
Tilray Portugal received its first manufacturing license and
initial GMP-certification, allowing the company to manufacture and
export bulk dried medical cannabis and wholesale dried cannabis as
active substances used as starting materials.
- Initial Export: In September 2019, Tilray completed its
first export to Germany from its EU campus in Portugal which was
one of the largest inter European bulk shipment of medical cannabis
to date. Thus far, Tilray has supplied medical cannabis products to
Germany and Israel from its EU campus in Portugal.
- Second GMP Certification: In December 2019, Tilray
Portugal received an additional GMP-certification which allowed
Tilray to supply international markets with pharmaceutical-grade
dried flower and oils as finished medical cannabis products.
Tilray has established sales and distribution arrangements to
supply medical cannabis through major pharmaceutical distribution
channels throughout Germany and other European markets. These
arrangements allow patients in need to access Tilray’s finished
medical cannabis products.
About Tilray® Tilray is a global pioneer in the research,
cultivation, production and distribution of cannabis and
cannabinoids currently serving tens of thousands of patients and
consumers in 15 countries spanning five continents.
Cautionary note regarding forward-looking statements:
This press release contains “forward-looking statements” within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995 and “forward-looking information” within the meaning of
Canadian securities laws, or collectively, forward-looking
statements. Forward-looking statements in this press release may be
identified by the use of words such as, “may”, “would”, “could”,
“will”, “likely”, “expect”, “anticipate”, “believe, “intend”,
“plan”, “forecast”, “project”, “estimate”, “outlook” and other
similar expressions. Forward-looking statements are not a guarantee
of future performance and are based upon a number of estimates and
assumptions of management in light of management’s experience and
perception of trends, current conditions and expected developments,
as well as other factors that management believes to be relevant
and reasonable in the circumstances, including assumptions in
respect of current and future market conditions, the current and
future regulatory environment and future approvals and permits.
Actual results, performance or achievement could differ materially
from that expressed in, or implied by, any forward-looking
statements in this press release, and, accordingly, you should not
place undue reliance on any such forward-looking statements, and
they are not guarantees of future results. Please see the heading
“Risk Factors” in Tilray’s Quarterly Report on Form 10-Q, which was
filed with the Securities and Exchange Commission on May 11, 2020,
and subsequent periodic reports, for a discussion of the material
risk factors that could cause actual results to differ materially
from the forward-looking information. Tilray does not undertake to
update any forward-looking statements that are included herein,
except in accordance with applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200527005054/en/
Global Media: Chrissy Roebuck, +1-833-206-8161, news@tilray.com
Investors: Raphael Gross, +1-203-682-8253,
raphael.gross@icrinc.com
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Apr 2023 to Apr 2024